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We assessed the frequency of short-term oral corticosteroid use in adults with diabetes, and 
examined the incidence of fractures, venous thromboembolism (VTE) and hospitalization for 
sepsis after corticosteroid use.  We also evaluated whether preventative medications mitigated 




We conducted a longitudinal study of 1,548,945 adults (ages 18-64 years) who received 
healthcare coverage through a large national health insurer, years 2012-2014.  Incidence rate 




Short-term oral corticosteroids were used by 23.9% of adults with type 2 diabetes, 20.8% with 
type 1, and 20.9% without diabetes during the 3-year period (p<0.001).  Baseline risks of 
fracture, VTE, and sepsis were greater for individuals with diabetes than those without 
(p<0.001).  The combined effect of having diabetes and using corticosteroids was greater than 
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the sum of the individual effects (synergy indices of 1.17, 1.23, 1.30 for fracture, VTE and 
sepsis, respectively). The IRR for venous thromboembolism was 3.62 (95% CI, 2.41-5.45) in the 
5-30 days after corticosteroid use.  Fractures increased in the 5-30 days after corticosteroid use 
(IRR=2.06, 95% CI: 1.52, 2.80), but concomitant use of ergocalciferol mitigated this risk 
(IRR=1.13; 95% CI: 0.12, 11.07). The risk of hospitalization for sepsis was elevated with 
corticosteroid use (IRR=3.79; 95% CI: 2.05, 7.01) but was mitigated by the concomitant use of 




Short-term oral corticosteroid use is common in adults with diabetes and is associated with an 
elevated, but low, risk of adverse events.  Our findings suggest that preventative medications 
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Vitamin D  






Adults with diabetes mellitus have a greater risk of fracture, venous thromboembolism, and 
sepsis than those without diabetes.  Use of corticosteroids, even for short durations, increases this 
risk.  However, vitamin D mitigated the risk of fracture in patients with diabetes who used 
corticosteroids.  Statins decreased the likelihood of hospitalization for sepsis in corticosteroid 
users with diabetes.  Corticosteroids should be used with caution in patients with diabetes and 
mitigating factors should be considered. 
 
  






Oral corticosteroids decrease insulin secretion, promote gluconeogenesis and glycogenolysis, 
and diminish hepatic and skeletal muscle insulin sensitivity (1); therefore, their use in patients 
with diabetes mellitus requires close surveillance.  Guidelines for diabetes management include 
recommendations for careful monitoring of blood glucose when beginning the use of oral 
corticosteroids and for caution when insulin dosing corrections are made to compensate for the 
anticipated hyperglycemia (2-4).  This is notable because corticosteroid use is common (5-7); for 
example, approximately one-fifth of the US working-age population uses short-term 
corticosteroids (8).  
 
Aside from hyperglycemia, the pleiotropic side effects of long-term oral corticosteroid use are 
well-recognized (9). Use for short periods has been generally considered safe, but recently has 
been implicated in risk, albeit at rather low frequencies (8).  Because adverse events may occur 
infrequently, it is not always possible to evaluate such risks within the context of a randomized 
controlled trial due to low statistical power.  Trials also impose a challenge for the evaluation of 
patient safety due to the dissimilarity of trial participants to the wider population of patients who 
may be taking the medications.  Moreover, many trials do not assess all risks; for example, 
investigators found that venous thromboembolism was not reported in 89% of randomized 
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controlled trials (10).  Therefore, the evaluation of patient safety is often undertaken during the 
post-trial period using data from a larger population of users.   
 
We were particularly interested in the safety of medications in the young- and middle-adult 
populations with diabetes because of the lack of studies in adults of working age.  We obtained 
data from a large, national sample of American adults who received private healthcare coverage.  
The purpose of our investigation was two-fold: (1) to assess the frequency of short-term oral 
corticosteroids in adults with diabetes, and (2) to examine the incidence of fractures, venous 
thromboembolism and hospitalization for sepsis by corticosteroid use.  Secondarily, we assessed 




We conducted a longitudinal study using de-identified data collected from January 1,2012 
through December 31, 2014 from adults (18-64 years of age) who received healthcare coverage 
through a large national health insurer (obtained through OptumInsight, Eden Prairie, Minnesota, 
USA).  The study was reviewed by the University of Michigan Institutional Review Board for 
oversight regarding human subjects, designated as exempt from further review, and given a 
waiver for informed consent.  There were 1,548,945 adults in the database, the methods of which 
have been described (8).  Briefly, adults with three years of continuous enrollment were included 
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to assess corticosteroid use and the incidence of fracture, venous thromboembolism and 
hospitalization for sepsis.  Since we were studying incident events, we excluded those 
individuals who experienced fractures, venous thromboembolism or sepsis in year 2011.  Over 
the 3-year period of the study (years 2012-2014), the first occurrence for each outcome was 
extracted so as to not capture follow-up visits for the same event. 
 
Oral corticosteroid use of short duration (<30 days) was extracted from pharmacy files, 
indicating the type of prescription(s) and the date(s) when filled.  Patients who were prescribed 
oral corticosteroids for >30 days cumulatively over the study period were excluded, as were 
those who received any oral corticosteroids during the year prior to the start of the study (in 
2011).  The oral corticosteroids identified were betamethasone, dexamethasone, 
methylprednisolone, triamcinolone, prednisone, prednisolone, hydrocortisone, and cortisone.  
We focused on oral corticosteroids that were swallowed (e.g., tablets, capsules, elixirs) and 
excluded all other forms of corticosteroids, including aerosols, creams, drops, suspended drops, 
lotion, spray and vials.   
 
Patients with type 1 diabetes mellitus were defined as individuals who had at least two ICD-9-
CM codes indicating type 1 diabetes on different dates, with the use of insulin (Table 1).  
Patients with type 2 diabetes were identified as individuals with records of at least two ICD-9-
CM codes indicating type 2 diabetes on different dates, regardless of type of antidiabetic 
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medication used (Table 1).  Outcomes (fracture, venous thromboembolism, sepsis) were also 
ascertained through ICD-9-CM codes.  For sepsis, hospital admissions were utilized in which the 
principal diagnosis was sepsis.  Fractures of the torso and limbs were included from injury codes 
(Table 1).  
 
There were no missing values for age or gender.  There were complete data regarding diagnoses 
and medication prescriptions that were filled by the participants within this health insurance plan 
during the time period of the study. 
 
There were several phases to the statistical analyses.  In the first phase, we examined the 
frequency of corticosteroid use (%, 95% exact confidence intervals (CI)), stratified by type of 
diabetes, gender, and age category.  To assess differences in the frequency of use by subgroup, 
Pearson’s chi-squared tests were used. 
 
In the second phase of the analyses, we assessed the frequency of the adverse events (fractures, 
venous thromboembolism, and hospitalization for sepsis).  Both cumulative incidence (%) and 
rates (events/1000 person-years) were calculated with 95% exact confidence intervals, stratified 
by type of diabetes.  Incidence rate ratios (IRR) were also calculated, comparing the event rate in 
corticosteroid users to that of non-steroid users, with stratification by type of diabetes.  The 
interaction between steroid use and diabetes on adverse events was determined by using the 
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synergy index on an additive scale (11).  A synergy index of >1.0 indicates a positive interaction; 
that is, the combined effect of having diabetes and using corticosteroids would be greater than 
the sum of the individual effects of these two factors.  In addition, we examined the association 
between corticosteroid use and adverse events when stratified by the type of anti-diabetic 
medication used (i.e., ever use during the study period); odds ratios were generated from a logit 
model with adjustment for age, gender, and race.  Heterogeneity by type of anti-diabetic 
medication was evaluated using Cochran’s Q test and the I2 statistic which measures the 
percentage of variation in the odds ratios (across the various anti-diabetic medications) that is 
due to heterogeneity rather than random error.     
 
In the third phase of the analyses, the association between corticosteroid use and adverse events 
was evaluated.  Using a self-controlled case series design, the incidence of adverse events after 
corticosteroid use was calculated and compared to the incidence of adverse events during the 
time period when the corticosteroid was not used.  That is, the incidence of events was compared 
in different time windows within the same person.  We assessed risk of adverse events in the 5-
30 days, 31-90 days, and 91-180 days after the corticosteroid prescription was filled.  The 
reference (comparator) period was 5-180 days prior to when the corticosteroid prescription was 
filled.  Conditional (fixed) Poisson regression was used for the analyses, offset by the natural 
logarithm of the time under observation. Incidence rate ratios were generated with 95% CI 
comparing the risk of adverse events when using versus not using corticosteroids.  Because this 
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was a within-person comparison, gender, race, genetic profile, history of past medical conditions, 
and past health-related behaviors remained the same.  Other non-steroidal medications that were 
significantly associated with the outcomes were included as time-varying covariates.   
 
In a secondary analysis of patients with diabetes, the self-controlled case series design was 
extended to examine whether the use of preventative medications at the same time as the 
corticosteroids affected the results.  Specifically, concomitant use (prescription filled 0-30 days 
prior to the corticosteroid prescription) of Vitamin D and statin was determined.  Use of 
corticosteroids with Vitamin D was of interest for the assessment of fractures.  Use of 
corticosteroids with statin was of interest for venous thromboembolism and sepsis.  Statistical 
methods were similar to those described above (i.e., fixed Poisson regression with an offset).  In 
addition, we utilized a cohort design to further investigate the association between concomitant 
medications and adverse events (comparing users to non-users) in which logistic regression was 
used. Alpha was set at 0.05, 2-tailed.  All analyses were conducted in Stata/MP 14.2 (StataCorp 
LP, College Station, Texas).   
 
RESULTS 
In this investigation, 8.1% (126091/1548945) of the adults had diabetes mellitus.  Of those with 
diabetes, 87.4% had type 2 (110141/126091) and 12.6% (15950/126091) had type 1 diabetes.  
The mean age of those with type 2 diabetes was 53.3 years (SD, 8.2), with type 1 diabetes was 
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49.5 years (SD, 11.4), and without diabetes was 43.6 years (SD, 12.1).  Men were more likely to 
have diabetes than women (60% males with type 1, 59% males with type 2, 54% males without 
diabetes; p<0.001).   
 
Within this database, 21.1% (327452/1548945) used corticosteroids for <30 days.  Individuals 
with type 2 diabetes were more likely to use corticosteroids than those with type 1 diabetes 
(p<0.001) and those without diabetes (p<0.001).  The frequency of corticosteroid use is given in 
Table 2, by diabetes type, gender, and age categories.  Women with type 2 diabetes were 
frequent users of short-duration corticosteroids (28.4% during the 3-year study period).  Across 
both gender and age categories, individuals with type 2 diabetes were more frequent users of 
corticosteroids than either those with type 1 or those without diabetes.  The mean duration of 
corticosteroid therapy in patients with diabetes was 6.7 days (SD, 3.0 days) and the median 
duration was 6 days (IQR: 5, 7 days).     
 
Rates of fracture, venous thromboembolism and hospitalization for sepsis are given in Table 3.  
Adults with type 1 diabetes had greater rates of adverse events than those with type 2 diabetes 
(p<0.001) and those without diabetes (p<0.001).  In adults with type 1 diabetes who used 
corticosteroids, 12.5% experienced a fracture, 4.6% experienced venous thromboembolism, and 
4.4% were hospitalized for sepsis during the study period.  This compares with 7.2%, 2.6%, and 
1.4% (respectively) for adults with type 2 diabetes.  The IRRs indicate that the risks of adverse 
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events were significantly elevated in patients with diabetes (both types 1 and 2) and in 
corticosteroid users (compared to nonusers without diabetes), although the strength of the 
association was greater in those with type 1 diabetes (Table 3). For example, the risk of venous 
thromboembolism was 7-fold greater in patients with type 1 diabetes who used corticosteroids 
compared to nonusers without diabetes.  All outcomes exhibited positive interactions (synergy 
indices of 1.17, 1.23, 1.30 for fracture, venous thromboembolism, and sepsis, respectively).  
Therefore, the combined effect of having diabetes and using corticosteroids was greater than the 
sum of the individual effects.   
 
When stratified by the type of anti-diabetic medication used, the association between 
corticosteroid use and adverse events remained (Figure 1).  The results indicate that there was no 
significant heterogeneity in the odds ratios, regardless of the outcome (p=0.360 fracture, p=0.962 
venous thromboembolism, p=0.465 sepsis).  I2 (measure of inconsistency) for fracture was 9.0%, 
for venous thromboembolism was 0%, and for sepsis was 0%.  Therefore, the odds for 
developing the three adverse events were significantly elevated for corticosteroid users 
(compared to non-users), regardless of the type of anti-diabetic medication used during the time 
period of the study. 
 
The results from the self-controlled case series are listed in Table 4.  The risk of adverse events 
was greatest during the 5-30 day period after the corticosteroid prescription was filled for those 
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with diabetes (IRR=2.06 for fracture, IRR=3.62 for venous thromboembolism, and IRR=3.79 for 
sepsis).  For all three outcomes, the incidence rate ratios tended to decrease over time. The 
results for those without diabetes are shown in Table 5, indicating that the relative risk of adverse 
events was similar for those with and without diabetes, although the underlying baseline risk was 
greater in those with diabetes (Table 3).   
 
We also evaluated the addition of potential preventative medications on the relationship between 
corticosteroids and adverse events in individuals with diabetes.  In this study, 11.4% 
(14376/126091) of individuals with diabetes used vitamin D, and 97.6% of the prescriptions 
were for 50,000 IU weekly of ergocalciferol (mean number of refills=5.7, SD=7.2).  Results 
from the self-controlled case series (Table 4) indicate that adults with diabetes had a 2-fold 
increase in the incidence of fracture in the 5-30 day period after the corticosteroid prescription 
was filled.  However, those patients with diabetes who were taking vitamin D with the 
corticosteroids did not experience an increased risk (IRR=1.13).  Those taking corticosteroids 
without vitamin D had an elevated risk (IRR=2.09).  We also examined the risk of fracture using 
the conventional cohort design, comparing individuals with diabetes who used versus did not use 
the medications (Table 6).  The risk of fracture was lowest (4.4%) in adults with diabetes who 
used vitamin D but no corticosteroids.  The highest risk of fracture was 8.1% in adults with 
diabetes who used corticosteroids but no vitamin D.  The odds of fracture were 1.37 times 
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greater in those using corticosteroids without vitamin D compared to those who did not use 
either of these medications.   
 
In this database, 61.4% (77419/126091) of individuals with diabetes ever used statins during the 
3-year study period.  The risk of venous thromboembolism was elevated (IRR=3.62) during the 
5-30 day period after the corticosteroid was taken (Table 4), but this risk declined over time.  
Results from the self-controlled case series indicated that the addition of statins did not 
appreciably affect the rate ratios for venous thromboembolism; the risk remained elevated 
regardless of statin use. For sepsis, however, the use of corticosteroids without statin yielded a 
significant IRR of 4.91 (Table 4).  When patients with diabetes used statins concomitantly with 
the corticosteroids, there was no significant elevation in sepsis risk.   
 
We also evaluated corticosteroids with statins using the conventional cohort approach (Table 6).  
The greatest risk of an adverse event occurred in adults with diabetes who used corticosteroids 
without statins (3.3% for venous thromboembolism, 2.1% for sepsis).  The odds of venous 
thromboembolism were 51% greater in those using corticosteroids without statins compared to 
those using neither (Table 6).  But the odds of venous thromboembolism were not elevated when 
the corticosteroids were used with statins (OR=1.04).  In addition, the odds of hospitalization for 
sepsis were lower when statins were used concomitantly with corticosteroids (OR=0.77) when 
compared to using neither; the (multiplicative) interaction term between corticosteroids and 
This article is protected by copyright. All rights reserved.
16 
 
statins was significant (p=0.013).  The use of statins modified the association between 




In this investigation, we found that adults with diabetes were frequent users of short-term oral 
corticosteroids.  Use was particularly common in type 2 diabetes, affecting 1 in 4 patients, while 
it occurred in 1 of 5 individuals with type 1 diabetes, and 1 in 5 persons without diabetes.  Short-
term use was higher in middle-aged adults compared to younger adults, and was frequent in 
women with type 2 diabetes, affecting 28.4% during the 3-year study period.  
 
The higher rates of fracture, venous thromboembolism, and hospitalization for sepsis in patients 
with diabetes confirm results from previous investigations (12-14).  But our study extends the 
current literature with the finding of synergy between diabetes and corticosteroid use.  The risks 
of adverse events were more elevated with these two factors together, than from each one 
separately.  This suggests that efforts to prevent adverse outcomes with oral corticosteroids may 
be better targeted to individuals with diabetes than those without.  Patients with type 1 diabetes 
may particularly benefit because of their higher baseline risk.  For individuals with type 2 
diabetes, the elevation in risk of adverse events after corticosteroid use remained, regardless of 
the type of anti-diabetic medications used.   




While there was an elevated risk of adverse events after corticosteroid use, the findings suggest 
that certain concomitant medications could possibly mitigate risk.  When individuals with 
diabetes used both corticosteroids and ergocalciferol (50,000 IU weekly), there was no elevated 
risk of fracture, but when corticosteroids were used without ergocalciferol, there was a 2-fold 
increased risk of fracture.  Data from the National Health and Nutrition Examination Survey, a 
nationally representative sample, demonstrated an association between corticosteroid use and 
25(OH)D deficiency (15).  In a meta-analysis of 25 studies, adults receiving corticosteroid 
therapy were found to have low serum 25(OH)D levels which were insufficient to prevent 
osteoporosis (16). The US Preventive Services Task Force reviewed the data and found 
inconclusive evidence regarding vitamin D supplementation on the risk of fractures in older 
adults, but there were no trials in high risk populations of middle-aged adults (17).  Our 
investigation found several high risk populations in adults 18-65 years of age; these include 
corticosteroid users and individuals with diabetes.  Our findings, suggesting that the use of 
50,000 IU of ergocalciferol may mitigate the effects of corticosteroid use in middle-aged adults 
with diabetes, should be confirmed in randomized controlled trials. Ergocalciferol is associated 
with minimal risk and it is significant that 42% of Americans (in general) are vitamin D 
deficient, as are 82% of African-Americans and 69% of Hispanics in the United States (18).  
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We also found that the use of statins influenced the association between corticosteroids and 
hospitalization for sepsis.  Both the self-controlled case series (within-person approach) and the 
cohort study (between-person approach) suggested that statins modified this association.  
Previous studies have shown that statins decrease the rate of severe sepsis and intensive care 
admissions (19-21). Moreover, rates of hospitalization for infection have been found to be 
significantly elevated in patients who use corticosteroids (22) and extended corticosteroid use 
has long been associated with immunosuppression and higher infection rates (1).  Because statin 
use is recommended for many adults with diabetes (based on the estimated 10-year 
cardiovascular disease risk) (23,24), randomized trials may be necessary to more clearly 
delineate potential benefits of adding statins to short-term corticosteroids for those patients with 
diabetes who are not currently receiving statins.      
 
There are limitations of this study.  Information was not available on levels of C-peptide and 
glutamic acid decarboxylase autoantibodies for all individuals with diabetes.  The use of ICD-9-
CM diagnosis codes and medication use to discern diabetes may have resulted in some 
misclassification. However, validation studies indicate that the use of 250xx diagnosis codes for 
diabetes (captured over a 1 year period) had a sensitivity of 97%, specificity of 97%, and positive 
predictive value of 98% (25).  In a study to distinguish diabetes type, the use of two or more type 
1 diagnosis codes yielded a sensitivity of 90% (26) and a positive predictive value of 91.3% for 
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the identification of type 1 diabetes (27).  A prescription for insulin had a sensitivity of 95% for 
type 1 diabetes (26). 
 
Another limitation is that we could not rule out confounding by indication; that is, the illness that 
prompted the patient’s visit to the physician could be a contributing factor of the adverse event.  
However, infection, thromboembolism, and decreases in bone density are all listed as possible 
adverse events on Food and Drug Administration package inserts of corticosteroids, indicating 
prior evidence of association (28,29).  With the use of short-term oral corticosteroids, we found 
that the absolute risk of such adverse effects was modest; for example, of 1000 patients with type 
1 diabetes who used corticosteroids, 43 experienced a fracture over a 1-year period.  This 
compared with 32 patients experiencing a fracture who did not use corticosteroids.    
 
The use of a self-controlled case series is a particularly strong design for addressing other 
confounding factors.  Our findings cannot be explained by dissimilarities in genetic profiles for 
different individuals because the comparison was within the same person.  Likewise, other 
personal characteristics such as past history of venous thromboembolism, history of cancer, 
former smoking habits, and past personal characteristics were controlled.  Because the 
comparator is the person him/herself, these factors (and the interactions among such factors) are 
held constant.   
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We conclude that the use of oral corticosteroids for short durations is common in patients with 
diabetes and is associated with an elevated (but modest) risk of fracture, venous 
thromboembolism and hospitalization for sepsis.  The addition of ergocalciferol to prevent 
fractures and the addition of statins to prevent hospitalization for sepsis should be investigated in 
randomized trials, particularly in patients with diabetes who use corticosteroids.    
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FIGURE 1.  Odds Ratios for the Association between Corticosteroid Use and Adverse Events by 
Type of Anti-Diabetic Medication 
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TABLE 2.  Short-Duration Oral Corticosteroid Use by Type of Diabetes, Age, and Gender 
                    
   
Steroid Use 
 
No Steroid Use 
        n/N %   n/N %   p value 
Overall 
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Age >40 years 
        
 












    No Diabetes   200808/900938 22.3%   700130/900938 77.7%   <0.001 
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TABLE 3.  Frequency of Adverse Events by Corticosteroid Use and Type of Diabetes 
                











Ratio 95% CI 
Synergy Index 
(95% CI)†     
Fracture: 
       
 
No Steroids, No Diabetes 45,969 
   
1,125,018  4.1% 13.9 (13.8, 14.0) 1.00 (reference) 
 
 
No Steroids, Type 1 Diabetes 1,161 
         
12,634  9.2% 32.2 (30.4, 34.1) 2.31 2.18, 2.45 
 
 
No Steroids, Type 2 Diabetes 4,223 
         
83,841  5.0% 17.2 (16.7, 17.8) 1.24 1.20, 1.28 
 
 
Steroids, No Diabetes 17,784 
       
297,836  6.0% 20.7 (20.3, 21.1) 1.49 1.46, 1.52 
 
 
Steroids, Type 1 Diabetes 414 
           
3,316  12.5% 43.3 (37.7, 49.6) 3.11 2.70, 3.57 
 
 
Steroids, Type 2 Diabetes 1,892 
         
26,300  7.2% 26.3 (24.7, 27.9) 1.89 1.78, 2.01 1.17 (1.12, 1.23) 
         Venous Thromboembolism: 
       
 
No Steroids, No Diabetes 7,136 
   
1,125,018  0.6% 2.1 (2.1, 2.2) 1.00 (reference) 
 
 
No Steroids, Type 1 Diabetes 341 
         
12,634  2.7% 9.1 (8.2, 10.1) 4.30 3.85, 4.79 
 
 
No Steroids, Type 2 Diabetes 1,418 
         
83,841  1.7% 5.7 (5.4, 6.0) 2.68 2.53, 2.84 
 
 
Steroids, No Diabetes 3,513        1.2% 4.1 (3.9, 4.3) 1.93 1.84, 2.03 
 





Steroids, Type 1 Diabetes 151 
           
3,316  4.6% 14.8 (11.8, 18.6) 6.98 5.48, 8.76 
 
 
Steroids, Type 2 Diabetes 679 
         
26,300  2.6% 8.8 (7.9, 9.8) 4.15 3.73, 4.61 1.23 (1.16, 1.29) 
         Hospitalization for Sepsis: 
       
 
No Steroids, No Diabetes 2,271 
   
1,125,018  0.2% 0.7 (0.6, 0.7) 1.00 (reference) 
 
 
No Steroids, Type 1 Diabetes 441 
         
12,634  3.5% 11.8 (10.8, 13.0) 17.58 15.84, 19.47 
 
 
No Steroids, Type 2 Diabetes 870 
         
83,841  1.0% 3.5 (3.2, 3.7) 5.16 4.77, 5.58 
 
 
Steroids, No Diabetes 1,040 
       
297,836  0.3% 1.3 (1.2, 1.4) 1.98 1.81, 2.16 
 
 
Steroids, Type 1 Diabetes 146 
           
3,316  4.4% 16.7 (13.5, 20.7) 24.87 19.79, 30.89 
 
  Steroids, Type 2 Diabetes 370 
         
26,300  1.4% 5.3 (4.7, 6.1) 7.94 6.89, 9.11 1.30 (1.23, 1.37) 
 
* per 1000 person-years at risk. 
       
 
† Synergy between diabetes and steroid use on an additive scale. 
     
 





TABLE 4.  Incidence Rate Ratios for Adverse Events Associated with Corticosteroids and Concomitant Medications in Individuals 
with Diabetes 
 
                 5-30 days*   31-90 days*   91-180 days* 
Event Medications 
IRR† 95% CI 
P 
value 




           
 
Corticosteroids 2.06 1.52, 2.80 <0.001 
 
1.66 1.29, 2.13 <0.001 
 
1.46 1.16, 1.84 0.001 
 
Corticosteroids & Vitamin D 1.13 0.12, 11.07 0.915 
 
0.37 0.03, 4.44 0.436 
 
0.14 0.01, 2.82 0.197 
 
Corticosteroids & no Vitamin D 2.09 1.53, 2.84 <0.001 
 
1.70 1.32, 2.19 <0.001 
 
1.50 1.19, 1.89 0.001 
Venous thromboembolism: 
           
 
Corticosteroids 3.62 2.41, 5.45 <0.001 
 
1.51 1.00, 2.28 0.049 
 
0.90 0.60, 1.36 0.613 
 
Corticosteroids & Statin 3.86 1.74, 8.59 0.001 
 
1.43 0.58, 3.52 0.440 
 
1.41 0.68, 2.94 0.353 
 
Corticosteroids & no Statin 3.33 2.05, 5.42 <0.001 
 
1.51 0.95, 2.42 0.083 
 
0.73 0.44, 1.21 0.223 
Sepsis: 
            
 
Corticosteroids 3.79 2.05, 7.01 <0.001 
 
2.64 1.44, 4.85 0.002 
 
1.64 0.89, 3.00 0.110 
 
Corticosteroids & Statin 1.62 0.45, 5.85 0.458 
 
1.91 0.68, 5.39 0.219 
 
1.02 0.33, 3.09 0.978 
  Corticosteroids & no Statin 4.91 2.31, 10.46 <0.001   2.73 1.26, 5.94 0.011   1.99 0.92, 4.30 0.078 
     *  Reference period was 5 to 180 days prior to prescription date. 
        
     † Sepsis was adjusted for antibiotics, 5-HT3 receptor antagonists, antidepressants, anti-inflammatory agents, antimuscarinics, opiate agonists, 
and phenothiazine. Venous thromboembolism was adjusted for antibiotics, androgens, anxiolytics, anti-inflammatory agents, azoles, calcium 
channel blockers, coumarin, diuretics, opiate agonists, and platelet-aggregation inhibitors. Fractures were adjusted for anti-inflammatory agents, 
COX-2 inhibitors, and opiate agonists. 












TABLE 5. Incidence Rate Ratios for Adverse Events Associated with Short-Term Oral Corticosteroid Use by Diabetes 
 
                 5-30 days*   31-90 days*   91-180 days* 
Adverse 
Event Condition 
IRR† 95% CI P value   IRR† 95% CI P value   IRR† 95% CI P value 
Fracture: 
            
 
Diabetes 2.06 1.52, 2.80 <0.001 
 
1.66 1.29, 2.13 <0.001 
 
1.46 1.16, 1.84 0.001 
 
No diabetes 1.85 1.66, 2.05 <0.001 
 
1.37 1.25, 1.51 <0.001 
 
1.27 1.17, 1.39 <0.001 
Venous thromboembolism: 
           
 
Diabetes 3.62 2.41, 5.45 <0.001 
 
1.51 1.00, 2.28 0.049 
 
0.90 0.60, 1.36 0.613 
 
No diabetes 3.25 2.66, 3.98 <0.001 
 
1.43 1.15, 1.76 0.001 
 
1.21 0.99, 1.47 0.065 
Sepsis: 
            
 
Diabetes 3.79 2.05, 7.01 <0.001 
 
2.64 1.44, 4.85 0.002 
 
1.64 0.89, 3.00 0.110 
  No diabetes 6.10 4.07, 9.15 <0.001   2.88 1.86, 4.47 <0.001   1.92 1.26, 2.93 0.003 
      * Reference period was 5 to 180 days prior to prescription date. 
            † Sepsis was adjusted for antibiotics, 5-HT3 receptor antagonists, antidepressants, anti-inflammatory agents, antimuscarinics, 
opiate agonists, and phenothiazine. Venous thromboembolism was adjusted for antibiotics, androgens, anxiolytics, anti-
inflammatory agents, azoles, calcium channel blockers, coumarin, diuretics, opiate agonists, and platelet-aggregation inhibitors. 

















Table 6. Frequency of Adverse Events for Individuals with Diabetes, by Type of Medication  
                







Event Odds Ratio*  95% CI p value 
Fracture: 
      
 
no Corticosteroids, no Vitamin D 4928 86103 5.7% 1.0 (reference) 
  
 
no Corticosteroids, Vitamin D 456 10372 4.4% 0.75 0.68, 0.83 <0.001 
 
Corticosteroids, no Vitamin D 2068 25612 8.1% 1.37 1.30, 1.45 <0.001 
 
Corticosteroids, Vitamin D 238 4004 5.9% 0.98 0.86, 1.12 0.798 
        Venous thromboembolism: 
     
 
no Corticosteroids, no Statins 821 37792 2.2% 1.0 (reference) 
  
 
no Corticosteroids, Statins 938 58683 1.6% 0.66 0.60, 0.72 <0.001 
 
Corticosteroids, no Statins 356 10880 3.3% 1.51 1.33, 1.71 <0.001 
 
Corticosteroids, Statins 474 18736 2.5% 1.04 0.92, 1.16 0.533 
        Sepsis: 
      
 
no Corticosteroids, no Statins 689 37792 1.8% 1.0 (reference) 
  
 
no Corticosteroids, Statins 622 58683 1.1% 0.52 0.46, 0.58 <0.001 
 
Corticosteroids, no Statins 224 10880 2.1% 1.14 0.98, 1.33 0.090 
  Corticosteroids, Statins 292 18736 1.6% 0.77 0.67, 0.88 <0.001 
 
    * Odds ratio adjusted for age, gender, and race. 
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